参考文献/References:
[1]Waheed Y,Yang F,Sun D.Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease[J].Korean J Intern Med,2021,36(6):1281-1293.[2]Li Q,Li X,Wang J,et al.Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements[J].BMJ Open,2019,9(8):e026677. [3]Pavelcova K,Bohata J,Pavlikova M,et al.Evaluation of the Influence of Genetic Variants of SLC2A9 (GLUT9) and SLC22A12 (URAT1) on the Development of Hyperuricemia and Gout[J].J Clin Med,2020,9(8):2510.[4]Yu W,Cheng JD.Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective[J].Front Pharmacol,2020(11):582680.[5]Bhatnagar V,Richard EL,Wu W,et al.Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling[J].Clin Kidney J,2016,9(3):444-453.[6]Tan PK,Liu S,Gunic E,et al.Discovery and characterization of verinurad,a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout[J].Sci Rep,2017,7(1):665.[7]Zhang L,Huang SM,Reynolds K,et al.Transporters in Drug Development: Scientific and Regulatory Considerations[J].Clin Pharmacol Ther,2018,104(5):793-796.[8]Kimoto E,Mathialagan S,Tylaska L,et al.Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs[J].J Pharmacol Exp Ther,2018,367(2):322-334.[9]Wang Q,Wen X,Kong J.Recent Progress on Uric Acid Detection: A Review[J].Crit Rev Anal Chem,2020,50(4):359-375.[10]Méndez-Salazar EO,Martínez-Nava GA.Uric acid extrarenal excretion: the gut microbiome as an evident yet understated factor in gout development[J].Rheumatol Int,2021,Epub ahead of print.[11]Vaziri ND,Freel RW,Hatch M.Effect of chronic experimental renal insufficiency on urate metabolism[J].J Am Soc Nephrol,1995,6(4):1313-1317.[12]Bardin T,Richette P.Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options[J].BMC Med,2017,15(1):123.[13]中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J].中华内分泌代谢杂志,2020,36(1):1-13.[14]Zhu Y,Pandya BJ,Choi HK.Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008[J].Arthritis Rheum,2011,63(10):3136-3141.[15]Wilson S,Mone P,Jankauskas SS,et al.Chronic kidney disease: Definition,updated epidemiology,staging,and mechanisms of increased cardiovascular risk[J].J Clin Hypertens (Greenwich),2021,23(4):831-834.[16]Kielstein JT,Pontremoli R,Burnier M.Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection[J].Curr Hypertens Rep,2020,22(12):102.[17]Li L,Yang C,Zhao Y,et al.Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies[J].BMC Nephrol,2014(15):122.[18]Tsai CW,Lin SY,Kuo CC,et al.Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review[J].PLoS One,2017,12(1):e0170393.[19]Tsai CW,Chiu HT,Huang HC,et al.Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses[J].Nephrol Dial Transplant,2018,33(2):231-241.[20]Kang DH.Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells[J].Contrib Nephrol,2018(192):48-55.[21]Zhang J,Lin X,Xu J,et al.Apelin-13 reduces oxidative stress induced by uric acid via downregulation of renin-angiotensin system in adipose tissue[J].Toxicol Lett,2019(305):51-57.[22]Komendarek-Kowalska M.The assessment of renal function in patients with newly diagnosed hypertension - the role of hyperuricemia as a risk factor for chronic kidney disease - preliminary study[J].Pol Merkur Lekarski,2017,42(251):193-196.[23]Yanai H,Adachi H,Hakoshima M,et al.Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome,Cardiovascular Diseases and Chronic Kidney Disease[J].Int J Mol Sci,2021,22(17):9221.[24]Liu J,Chen L,Yuan H,et al.Survey on uric acid in Chinese subjects with essential hypertension (SUCCESS): a nationwide cross-sectional study[J].Ann Transl Med,2021,9(1):27.[25]Grayson PC,Kim SY,La Valley M,et al.Hyperuricemia and incident hypertension: a systematic review and meta-analysis[J].Arthritis Care Res (Hoboken),2011,63(1):102-110.[26]Wang J,Qin T,Chen J,et al.Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies[J].PLoS One,2014,9(12):e114259.[27]De Cosmo S,Viazzi F,Pacilli A,et al.Serum Uric Acid and Risk of CKD in Type 2 Diabetes[J].Clin J Am Soc Nephrol,2015,10(11):1921-1929.[28]Chen MY,Wang AP,Wang JW,et al.Coexistence of hyper-uricaemia and low urinary uric acid excretion further increases risk of chronic kidney disease in type 2 diabetes[J].Diabetes Metab,2019,45(6):557-563.[29]Kim DG,Choi HY,Kim HY,et al.Association between post-transplant serum uric acid levels and kidney transplantation outcomes[J].PLoS One,2018,13(12):e0209156.[30]Magott-Procelewska M,Madziarska K,Boratynska M,et al.Kidney Transplantation From Old Deceased Donors: Impact of Uric Acid Level-A Quarter-Century of Experience in One Transplant Center[J].Transplant Proc,2018,50(6):1701-1704.[31]Eyupoglu S,Eyupoglu D,Kendi-Celebi Z,et al.Risk Factors of Hyperuricemia After Renal Transplantation and Its Long-term Effects on Graft Functions[J].Transplant Proc,2017,49(3):505-508.[32]Sato Y,Feig DI,Stack AG,et al.The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD[J].Nat Rev Nephrol,2019,15(12):767-775.[33]Bonino B,Leoncini G,Russo E,et al.Uric acid in CKD: has the jury come to the verdict?[J].J Nephrol,2020,33(4):715-724.[34]Trevino-Becerra A.Uric Acid: The Unknown Uremic Toxin[J].Contrib Nephrol,2018(192):25-33.[35]Tsuruta Y,Mochizuki T,Moriyama T,et al.Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease[J].Clin Rheumatol,2014,33(11):1643-1648.[36]Bose B,Badve SV,Hiremath SS,et al.Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis[J].Nephrol Dial Transplant,2014,29(2):406-413.[37]Liu X,Zhai T,Ma R,et al.Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis[J].Ren Fail,2018,40(1):289-297.[38]Kojima S,Matsui K,Hiramitsu S,et al.Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntionStuDy[J].Eur Heart J,2019,40(22):1778-1786.[39]Lee JW,Lee KH.Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease[J].Int Urol Nephrol,2019,51(3):467-473.[40]Yang AY.Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases[J].Int J Clin Pharmacol Ther,2020,58(1):21-28.[41]Hsu YO,Wu IW,Chang SH,et al.Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis[J].Clin Pharmacol Ther,2020,107(5):1159-1169.
相似文献/References:
[1]孙 秋,万 明,冯会芳,等.高尿酸血症生化血常规特征分析[J].医学信息,2018,31(06):153.[doi:10.3969/j.issn.1006-1959.2018.06.054]
SUN Qiu,WAN Ming,FENG Hui-fang,et al.Analysis of Biochemical Blood Routine Characteristics of Hyperuricemia[J].Medical Information,2018,31(07):153.[doi:10.3969/j.issn.1006-1959.2018.06.054]
[2]谢 琴.肾小球C4d沉积在慢性肾病早期诊断及预后的价值分析[J].医学信息,2018,31(08):81.[doi:10.3969/j.issn.1006-1959.2018.08.025]
XIE Qin.Value of Glomerular C4d Deposition in Early Diagnosis and Prognosis of Chronic Kidney Disease[J].Medical Information,2018,31(07):81.[doi:10.3969/j.issn.1006-1959.2018.08.025]
[3]俞 瑞,吴建荣,杨晓萍,等.健康体检者中高尿酸人群血脂水平变化及
甘油三脂升高的相关因素分析[J].医学信息,2018,31(13):62.[doi:10.3969/j.issn.1006-1959.2018.13.018]
YU Rui,WU Jian-rong,YANG Xiao-ping,et al.Analysis of Related Factors of Blood Lipid Levels and Elevated Triglycerides in Hyperuricemia Population in Healthy Subjects[J].Medical Information,2018,31(07):62.[doi:10.3969/j.issn.1006-1959.2018.13.018]
[4]张 铭,徐 蔷,肖 帆,等.芹菜籽提取物对高尿酸血症模型大鼠的血尿酸以及
抗氧化能力的影响[J].医学信息,2018,31(13):84.[doi:10.3969/j.issn.1006-1959.2018.13.024]
ZHANG Ming,XU Qiang,XIAO Fan,et al.Effects of Celery Seed Extract on Serum Uric Acid and Antioxidant Capacity of Hyperuricemia Rats[J].Medical Information,2018,31(07):84.[doi:10.3969/j.issn.1006-1959.2018.13.024]
[5]杨 红,顾小红.体检人群尿酸与脂肪肝的相关性研究[J].医学信息,2018,31(18):57.[doi:10.3969/j.issn.1006-1959.2018.18.018]
YANG Hong,GU Xiao-hong.Correlation between Uric Acid and Fatty Liver in Physical Examination Population[J].Medical Information,2018,31(07):57.[doi:10.3969/j.issn.1006-1959.2018.18.018]
[6]朱树花.高尿酸血症与中青年无症状性脑梗死的相关性分析[J].医学信息,2019,32(04):107.[doi:10.3969/j.issn.1006-1959.2019.04.034]
ZHU Shu-hua.Correlation between Hyperuricemia and Asymptomatic Cerebral Infarction in Young and Middle-aged[J].Medical Information,2019,32(07):107.[doi:10.3969/j.issn.1006-1959.2019.04.034]
[7]彭琪彦.慢性肾脏病患者RBP与T淋巴细胞亚群
检测的临床意义[J].医学信息,2019,32(18):91.[doi:10.3969/j.issn.1006-1959.2019.18.029]
PENG Qi-yan.Clinical Significance of Detection of RBP and T Lymphocyte Subsets in
Patients with Chronic Kidney Disease[J].Medical Information,2019,32(07):91.[doi:10.3969/j.issn.1006-1959.2019.18.029]
[8]王云轩,冯 妍,朱平辉,等.社区医务人员高尿酸血症与生活方式的相关性[J].医学信息,2019,32(19):114.[doi:10.3969/j.issn.1006-1959.2019.19.036]
WANG Yun-xuan,FENG Yan,ZHU Ping-hui,et al.Correlation Between Hyperuricemia and Lifestyle in Community Medical Staff[J].Medical Information,2019,32(07):114.[doi:10.3969/j.issn.1006-1959.2019.19.036]
[9]崔方强.足细胞上皮间质转分化研究[J].医学信息,2019,32(22):21.[doi:10.3969/j.issn.1006-1959.2019.22.008]
CUI Fang-qiang.Epithelial Transdifferentiation of Podocytes[J].Medical Information,2019,32(07):21.[doi:10.3969/j.issn.1006-1959.2019.22.008]
[10]高 彬,孙 娜,常文秀.慢性肾脏病患者血钾异常相关因素分析[J].医学信息,2019,32(22):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
GAO Bin,SUN Na,CHANG Wen-xiu.Analysis of Related Factors of Serum Potassium Abnormality in Patients with Chronic Kidney Disease[J].Medical Information,2019,32(07):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
[11]倪 曼.非布司他与别嘌醇治疗慢性肾脏病合并高尿酸血症的疗效比较[J].医学信息,2020,33(15):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]
NI Man.Comparison of the Efficacy of Febuxostat Tablets and Allopurinol in the Treatment of Chronic Kidney Disease with Hyperuricemia[J].Medical Information,2020,33(07):140.[doi:10.3969/j.issn.1006-1959.2020.15.043]